292 related articles for article (PubMed ID: 27503607)
1. Protease-Responsive Prodrug with Aggregation-Induced Emission Probe for Controlled Drug Delivery and Drug Release Tracking in Living Cells.
Cheng Y; Huang F; Min X; Gao P; Zhang T; Li X; Liu B; Hong Y; Lou X; Xia F
Anal Chem; 2016 Sep; 88(17):8913-9. PubMed ID: 27503607
[TBL] [Abstract][Full Text] [Related]
2.
Dong Y; Du P; Liu P
Int J Pharm; 2020 Oct; 588():119723. PubMed ID: 32755688
[TBL] [Abstract][Full Text] [Related]
3. Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study.
Ryu JS; Kratz F; Raucher D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498762
[TBL] [Abstract][Full Text] [Related]
4. H
Liang YX; Sun XY; Xu DZ; Huang JR; Tang Q; Lu ZL; Liu R
Bioorg Chem; 2022 Feb; 119():105559. PubMed ID: 34952244
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
6. Polymeric prodrug microspheres with tumor intracellular microenvironment bioreducible degradation, pH-triggered "off-on" fluorescence and drug release for precise imaging-guided diagnosis and chemotherapy.
Pei M; Li G; Ma K; Li J; Wang Y; Liu P
Colloids Surf B Biointerfaces; 2019 May; 177():313-320. PubMed ID: 30771583
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug.
Jiang J; Shen N; Ci T; Tang Z; Gu Z; Li G; Chen X
Adv Mater; 2019 Nov; 31(44):e1904278. PubMed ID: 31549774
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional Polymeric Prodrug with Simultaneous Conjugating Camptothecin and Doxorubicin for pH/Reduction Dual-Responsive Drug Delivery.
Dong S; Sun Y; Liu J; Li L; He J; Zhang M; Ni P
ACS Appl Mater Interfaces; 2019 Mar; 11(9):8740-8748. PubMed ID: 30693750
[TBL] [Abstract][Full Text] [Related]
9. Photo- and pH- Dual-Responsive β-Cyclodextrin-Based Supramolecular Prodrug Complex Self-Assemblies for Programmed Drug Delivery.
Bai Y; Liu CP; Song X; Zhuo L; Bu H; Tian W
Chem Asian J; 2018 Dec; 13(24):3903-3911. PubMed ID: 30311448
[TBL] [Abstract][Full Text] [Related]
10. Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy.
Yoo J; Sanoj Rejinold N; Lee D; Jon S; Kim YC
J Control Release; 2017 Oct; 264():89-101. PubMed ID: 28842316
[TBL] [Abstract][Full Text] [Related]
11. Probe-inspired nano-prodrug with dual-color fluorogenic property reveals spatiotemporal drug release in living cells.
Xue X; Jin S; Zhang C; Yang K; Huo S; Chen F; Zou G; Liang XJ
ACS Nano; 2015 Mar; 9(3):2729-39. PubMed ID: 25688453
[TBL] [Abstract][Full Text] [Related]
12. Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity.
Zhang A; Yao L; An M
Chem Commun (Camb); 2017 Nov; 53(95):12826-12829. PubMed ID: 29143021
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-responsive cell-penetrating peptide conjugated mesoporous silica quantum dot nanocarriers for controlled release of nucleus-targeted drug molecules and real-time intracellular fluorescence imaging of tumor cells.
Li J; Liu F; Shao Q; Min Y; Costa M; Yeow EK; Xing B
Adv Healthc Mater; 2014 Aug; 3(8):1230-9. PubMed ID: 24550203
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
[TBL] [Abstract][Full Text] [Related]
15. Rod-like cellulose nanocrystal/cis-aconityl-doxorubicin prodrug: A fluorescence-visible drug delivery system with enhanced cellular uptake and intracellular drug controlled release.
Li N; Lu W; Yu J; Xiao Y; Liu S; Gan L; Huang J
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():179-189. PubMed ID: 30033244
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug.
Liu W; Liang L; Zhao L; Tan H; Wu J; Qin Q; Gou X; Sun X
Bioorg Med Chem Lett; 2019 Feb; 29(3):487-490. PubMed ID: 30553736
[TBL] [Abstract][Full Text] [Related]
17. H
Dai YD; Sun XY; Sun W; Yang JB; Liu R; Luo Y; Zhang T; Tian Y; Lu ZL; He L
Org Biomol Chem; 2019 Jun; 17(22):5570-5577. PubMed ID: 31114827
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma.
Dragojevic S; Mackey R; Raucher D
Molecules; 2019 Sep; 24(18):. PubMed ID: 31489879
[TBL] [Abstract][Full Text] [Related]
19. Redox-responsive tetraphenylethylene-buried crosslinked vesicles for enhanced drug loading and efficient drug delivery monitoring.
Yu Y; Chen Y; Huang J; Wang L; Gu Z; Zhang S
J Mater Chem B; 2019 Dec; 7(47):7540-7547. PubMed ID: 31720682
[TBL] [Abstract][Full Text] [Related]
20. Intracellularly Actuated Quantum Dot-Peptide-Doxorubicin Nanobioconjugates for Controlled Drug Delivery via the Endocytic Pathway.
Sangtani A; Petryayeva E; Wu M; Susumu K; Oh E; Huston AL; Lasarte-Aragones G; Medintz IL; Algar WR; Delehanty JB
Bioconjug Chem; 2018 Jan; 29(1):136-148. PubMed ID: 29191007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
